市場調查報告書
商品編碼
1284073
到 2028 年的電子皮膚貼片市場預測-按產品、組件、傳感器、產品類型、銷售渠道、分銷渠道、應用和地區分列的全球分析Electronic Skin Patch Market Forecasts to 2028 - Global Analysis By Product, By Component, By Sensor, By Type, By Sales Channel, By Distribution Channel, By Application and By Geography |
根據 Stratistics MRC,2022 年全球電子皮膚貼片市場將達到 82.7 億美元,預測期內復合年增長率為 22.5%,預計 20.28 億美元達到 279.5 億美元.
皮膚貼片通過將它們貼在皮膚上來使用。 電子元件集成了傳感器、執行器、處理器和通信等電子功能,使設備能夠交互並變得“智能”。 皮膚貼片在許多方面都可以作為理想的可穿戴電子產品,以最輕的重量和最高的舒適度提升佩戴者的體驗。
根據世界衛生組織發布的一份報告,2016年有4.22億成年人患有糖尿病,而且這一數字預計還會增加,從而為電子皮膚貼片市場提供了機會。。
電子皮膚由於具有自愈性和柔韌性等優點,正在得到越來越廣泛的應用。 合成皮膚接近人類感官,可用於各種健康監測技術。 由於其最重要的特性、敏感性和靈活性,人體皮膚在可穿戴技術中是獨一無二的。 此外,越來越多的產品發布和 FDA 的快速批准正在推動市場增長。 例如,2018 年 5 月,FDA 批准了 MC10, Inc. 的 BioStamp nPoint 系統。
由於傳統貼片的缺點,光伏系統越來越多地用於皮膚貼片和傳感器。 傳統的皮膚貼片有很多局限性,例如需要為設備充電,因此難以同時監測多人的健康狀況。 此外,濕度等環境因素會降低電子皮膚貼片的性能,限制其適用性並製約市場擴張。
在預測期內,市場預計將受益於公眾日益增強的健身導向。 電子皮膚貼片有望在醫療保健領域發揮作用,因為它們只需使用粘合劑即可監測生理過程,而無需進行侵入性治療。 然而,消費者對可穿戴電子領域電子皮膚解決方案的需求不斷增長以及技術進步預計將提振市場。
限制市場擴張的主要障礙。 初始成本高、設計困難、缺乏數據安全性和不兼容性阻礙了電子皮膚貼片的採用。
COVID-19 疫情引發了全球性問題。 世界已經完全停滯,許多企業都在為維持利潤、失業和經濟危機而苦苦掙扎。 醫療保健行業受到患者激增和護理不足的沉重打擊。 隨著死亡人數的增加,個人恐慌情況變得更糟。 貿易停滯不前,衣食住行困難重重。 由於封鎖和業務關閉,COVID-19 大流行對全球電子皮膚貼片行業產生了不利影響。 供應鍊和分銷鏈受到限制,導致公司蒙受損失。
心血管監測預計在預測期內將佔據最大的市場份額,因為心血管監測對於運動員來說非常重要,因為馬拉松跑很多公裡超過了人體的能力。 對於運動員來說,監測心肺健康對於跑得更好至關重要。 包括心率、前負荷、收縮力和後負荷在內的四個因素相互關聯以產生心臟功能。
在預測期內,由於可穿戴電子設備與人體皮膚直接接觸,會因人體運動而發生伸長和扭曲等各種變形,因此市場對可伸縮電路的需求有望增長身體。增加。 可伸縮電路可以為電子皮膚貼片提供廣泛的功能可能性,例如定制的醫療保健監控和人體運動檢測。 此外,使用可伸縮電路可以在不干擾日常生活的情況下測量各種生物信號。
預計在預測期內,歐洲將佔據最大份額,因為傳統的糖尿病監測方法使用葡萄糖試紙和手指點刺試驗來監測血糖水平。 因此,在 2018 年 4 月,英國巴斯大學的科學家創造了一種粘性電子皮膚貼片,可以每 10-15 分鐘測量一次血糖水平,以防止使用此類侵入性程序。。
在預測期內,亞太地區將主導全球電子皮膚貼片市場,因為技術進步能夠創造出改進的電子皮膚貼片,而且該地區對設備的接受率很高。預計該地區將展示增長率最高。 此外,由於醫療保健基礎設施的擴大,它預計將實現最高增長。 然而,增加研發業務的資金是該地區市場擴張的原因。
2023 年 4 月,雅培宣布完成對 Cardiovascular Systems, Inc. (CSI) 的收購,這是一家醫療設備公司,擁有用於治療外周動脈和冠狀動脈疾病的創新型粥樣斑塊切除術系統。. 通過此次收購,雅培將提供治療血管疾病的補充解決方案。 CSI 的主要粥樣斑塊切除術系統準備血管並恢復血流,用於血管成形術和支架置入術。
2020年2月,Vital Connect宣布將部署可穿戴生物傳感器“VitalPatch”,並配備遠程監測平台,監測11種具有心律失常檢測功能的生命體徵測量。
2019 年 1 月,霍爾斯特中心宣布推出一次性健康貼片,用於測量與人類健康相關的生命體徵。 這個突破性的健康補丁的一項重要技術改進是將各種傳感器整合到 imec 的 MUSEIC V3 SoC 解決方案中。
According to Stratistics MRC, the Global Electronic Skin Patch Market is accounted for $8.27 billion in 2022 and is expected to reach $27.95 billion by 2028 growing at a CAGR of 22.5% during the forecast period. Skin patches are objects that can be used and are affixed to the skin. The electronic component entails integrating electronic features, including sensors, actuators, processors, and communication, which enable the devices to interact with one another and become "smart." Skin patches serve as the ideal wearable electronic gadgets in many aspects, enhancing the wearer with the least amount of weight and the highest level of comfort.
According to a report published by WHO, in 2016, there were 422 million adults suffering from diabetes and this number is expected to grow, thus providing opportunities for the electronic skin patch market.
Electronic skin is becoming more widely used as a result of its benefits, including self-healing and flexibility. Synthetic skin can be used in a wide range of health monitoring technologies as it closely resembles human sensory capacities. Human skin is unique among wearable technologies because of its sensitivity and flexibility, which are two of its most significant properties. Additionally, accelerating market growth are the rising number of product launches and rapid FDA approvals. For instance, the FDA approved the BioStamp nPoint system from MC10, Inc. in May 2018.
Photovoltaic systems are being utilized in skin patches and sensors more frequently due to the drawbacks of conventional patches. Traditional skin patches have a number of limitations, such as the need to charge the device, which has made it difficult for several individuals to monitor their health. Additionally, environmental factors like moisture and others degrade electronic skins patches, restricting their adaptability and constraining market expansion.
During the forecast period, the market is anticipated to benefit from the population's growing trend toward fitness. Electronic skin patches are expected to be advantageous for the healthcare sector because they do not require invasive treatments and only require an adhesive to monitor physiological processes. However, the market will expand as a result of rising consumer demand for electronic skin solutions in the wearable electronics sector as well as technological advancement.
There are significant obstacles that are limiting market expansion. The adoption of electronic skin patches is being hampered by issues like the high initial cost, challenging design, lack of data security, and lack of compatibility.
The COVID-19 epidemic sparked a problem that spread around the globe. Due to the complete shutdown of the world, many firms struggled to maintain revenue, which resulted in job losses and an economic crisis. The surge in patients and inadequate care caused the healthcare industry to suffer severely. The panic scenario among individuals grew worse as the death toll increased. Trades were slowed down or stopped altogether, and it was difficult to obtain the simplest necessities. Due to lockdowns and business closures, the COVID-19 pandemic had a negative effect on the global electronic skin patch industry. The supply and distribution networks were restricted, which resulted in losses for the company.
Cardiovascular monitoring is expected to hold the largest market share over the extrapolated period, because running marathons over many kilometers involves pushing beyond the capabilities of the human body, cardiovascular monitoring crucial for athletes. It has become crucial for athletes to monitor their heart function in order to better organize their runs. Four interconnected factors, including heart rate, preload, contractility, and afterload, result in cardiac function.
Due to wearable electronic devices attached in direct contact with human skin incorporating various deformations such as elongation and twisting resulting from human body movement, the demand for stretchable circuits is anticipated to have lucrative growth in the market throughout the forecast period. Stretchable circuits have the potential to enable a wide range of functional possibilities for electronic skin patches, including customized healthcare monitoring and human motion detection. Additionally, the stretchable circuits make it possible to measure a variety of biosignals without disrupting daily activities.
Because traditional methods of diabetes monitoring involve the use of glucose strips and finger-prick tests to monitor blood glucose levels, Europe is anticipated to have the largest share over the forecasted period. Thus, in April 2018, scientists from the University of Bath in the United Kingdom created an adhesive electronic skin patch that can measure blood glucose levels every 10-15 minutes in order to prevent the use of such invasive procedures.
Due to technological improvements that enabled the creation of improved electronic skin patches and a high acceptance rate for the devices in the area, the Asia-Pacific region was predicted to have the highest growth rate for the global market for electronic skin patches over the projected period. Furthermore, because of the expanding healthcare infrastructure, it is predicted to experience the highest growth. However, the rise in financing for R&D operations is accountable for the market expansion in this region.
Some of the key players in Electronic Skin Patch market include 3M, Abbott Laboratories, BioTelemetry, Inc., DexCom, Inc., Dialog Semiconductor, GE Healthcare, General Electric Company, Insulet Corporation, Intelesens Ltd., iRhythm Technologies Inc., Koninklijke Philips N.V., Leaf Healthcare Inc., Loreal SA, MC10, Medtronic, Plc., Nemaura Medical Inc., Omron Corporation, Physical Optics Corporation, Plastic Electronics GmbH, Quad industries SA, Senseonics Holding, Inc., Sensium Healthcare Ltd , Vitalconnect Inc. and VivaLNK.
In April 2023, Abbott announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow.
In February 2020, VitalConnect made an announcement about the inclusion of arrhythmia detection functionality to its remote monitoring platform that deploys wearable biosensor, VitalPatch, to monitor the measurement of eleven vital signs.
In January 2019, Holst Centre announced the launch of a disposable health patch for taking measurements of vital signs associated with human health. An essential technology enhancement in this groundbreaking health patch is incorporating an extensive range of sensors into MUSEIC V3 SoC solution by imec.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.